Literature DB >> 21541002

Physio-pathological roles of transglutaminase-catalyzed reactions.

Mariangela Ricotta1, Maura Iannuzzi, Giulia De Vivo, Vittorio Gentile.   

Abstract

Transglutaminases (TGs) are a large family of related and ubiquitous enzymes that catalyze post-translational modifications of proteins. The main activity of these enzymes is the cross-linking of a glutaminyl residue of a protein/peptide substrate to a lysyl residue of a protein/peptide co-substrate. In addition to lysyl residues, other second nucleophilic co-substrates may include monoamines or polyamines (to form mono- or bi-substituted /crosslinked adducts) or -OH groups (to form ester linkages). In the absence of co-substrates, the nucleophile may be water, resulting in the net deamidation of the glutaminyl residue. The TG enzymes are also capable of catalyzing other reactions important for cell viability. The distribution and the physiological roles of TG enzymes have been widely studied in numerous cell types and tissues and their roles in several diseases have begun to be identified. "Tissue" TG (TG2), a member of the TG family of enzymes, has definitely been shown to be involved in the molecular mechanisms responsible for a very widespread human pathology: i.e. celiac disease (CD). TG activity has also been hypothesized to be directly involved in the pathogenetic mechanisms responsible for several other human diseases, including neurodegenerative diseases, which are often associated with CD. Neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, supranuclear palsy, Huntington's disease and other recently identified polyglutamine diseases, are characterized, in part, by aberrant cerebral TG activity and by increased cross-linked proteins in affected brains. In this review, we discuss the physio-pathological role of TG-catalyzed reactions, with particular interest in the molecular mechanisms that could involve these enzymes in the physio-pathological processes responsible for human neurodegenerative diseases.

Entities:  

Keywords:  Celiac disease; Neurodegenerative diseases; Post-translational-modifications of proteins; Transglutaminase inhibitors; Transglutaminases

Year:  2010        PMID: 21541002      PMCID: PMC3083958          DOI: 10.4331/wjbc.v1.i5.181

Source DB:  PubMed          Journal:  World J Biol Chem        ISSN: 1949-8454


  64 in total

1.  Protein crosslinking, tissue transglutaminase, alternative splicing and neurodegeneration.

Authors:  Bruce A Citron; Zhiming Suo; Karen SantaCruz; Peter J A Davies; Frank Qin; Barry W Festoff
Journal:  Neurochem Int       Date:  2002-01       Impact factor: 3.921

2.  Transglutaminase bonds in neurofibrillary tangles and paired helical filament tau early in Alzheimer's disease.

Authors:  Steven M Singer; Gina M Zainelli; Maryam A Norlund; John M Lee; Nancy A Muma
Journal:  Neurochem Int       Date:  2002-01       Impact factor: 3.921

3.  Mapping and cloning of the critical region for the spinocerebellar ataxia type 1 gene (SCA1) in a yeast artificial chromosome contig spanning 1.2 Mb.

Authors:  S Banfi; M Y Chung; T J Kwiatkowski; L P Ranum; A E McCall; A C Chinault; H T Orr; H Y Zoghbi
Journal:  Genomics       Date:  1993-12       Impact factor: 5.736

4.  Transglutaminase activity is present in highly purified nonsynaptosomal mouse brain and liver mitochondria.

Authors:  Boris F Krasnikov; Soo-Youl Kim; Stephen J McConoughey; Hoon Ryu; Hui Xu; Irina Stavrovskaya; Siiri E Iismaa; Bryony M Mearns; Rajiv R Ratan; John P Blass; Gary E Gibson; Arthur J L Cooper
Journal:  Biochemistry       Date:  2005-05-31       Impact factor: 3.162

5.  Cystamine inhibits caspase activity. Implications for the treatment of polyglutamine disorders.

Authors:  Mathieu Lesort; Matthew Lee; Janusz Tucholski; Gail V W Johnson
Journal:  J Biol Chem       Date:  2002-11-27       Impact factor: 5.157

6.  Gluten T cell epitope targeting by TG3 and TG6; implications for dermatitis herpetiformis and gluten ataxia.

Authors:  Jorunn Stamnaes; Siri Dorum; Burkhard Fleckenstein; Daniel Aeschlimann; Ludvig M Sollid
Journal:  Amino Acids       Date:  2010-03-19       Impact factor: 3.520

7.  Autoantibodies in gluten ataxia recognize a novel neuronal transglutaminase.

Authors:  Marios Hadjivassiliou; Pascale Aeschlimann; Alexander Strigun; David S Sanders; Nicola Woodroofe; Daniel Aeschlimann
Journal:  Ann Neurol       Date:  2008-09       Impact factor: 10.422

8.  Structure of the gene for human transglutaminase 1.

Authors:  K Yamanishi; J Inazawa; F M Liew; K Nonomura; T Ariyama; H Yasuno; T Abe; H Doi; J Hirano; S Fukushima
Journal:  J Biol Chem       Date:  1992-09-05       Impact factor: 5.157

9.  Effect of tissue transglutaminase on the solubility of proteins containing expanded polyglutamine repeats.

Authors:  T-S Lai; T Tucker; J R Burke; W J Strittmatter; C S Greenberg
Journal:  J Neurochem       Date:  2004-03       Impact factor: 5.372

10.  Coagulation factor XIII serves as protein disulfide isomerase.

Authors:  Judith Lahav; Eli Karniel; Zsuzsa Bagoly; Vera Sheptovitsky; Rima Dardik; Aida Inbal
Journal:  Thromb Haemost       Date:  2009-05       Impact factor: 5.249

View more
  8 in total

Review 1.  γ-Glutamylamines and neurodegenerative diseases.

Authors:  Thomas M Jeitner; Kevin Battaile; Arthur J L Cooper
Journal:  Amino Acids       Date:  2012-03-10       Impact factor: 3.520

Review 2.  Lysyl oxidases in the trabecular meshwork.

Authors:  Robert J Wordinger; Abbot F Clark
Journal:  J Glaucoma       Date:  2014 Oct-Nov       Impact factor: 2.503

Review 3.  Post-translational modifications of tubulin: pathways to functional diversity of microtubules.

Authors:  Yuyu Song; Scott T Brady
Journal:  Trends Cell Biol       Date:  2014-11-25       Impact factor: 20.808

4.  Transglutaminase inhibition: A therapy to protect cells from death in neurodegeneration?

Authors:  Martina Iannaccone; Alessandro Stefanile; Giulia De Vivo; Antonio Martin; Enrica Serretiello; Vittorio Gentile
Journal:  World J Biol Chem       Date:  2012-11-26

Review 5.  Immune-mediated cerebellar ataxias: from bench to bedside.

Authors:  Hiroshi Mitoma; Mario Manto; Christiane S Hampe
Journal:  Cerebellum Ataxias       Date:  2017-09-21

6.  Transglutaminase Type 2 regulates the Wnt/β-catenin pathway in vertebrates.

Authors:  Federica Rossin; Roberto Costa; Matteo Bordi; Manuela D'Eletto; Luca Occhigrossi; Maria Grazia Farrace; Nickolai Barlev; Fabiola Ciccosanti; Silvia Muccioli; Leonardo Chieregato; Ildiko Szabo; Gian Maria Fimia; Mauro Piacentini; Luigi Leanza
Journal:  Cell Death Dis       Date:  2021-03-05       Impact factor: 8.469

7.  Characterisation of a novel cold-adapted calcium-activated transglutaminase: implications for medicine and food processing.

Authors:  Rebeca Garcia Alvarez; Pralav Karki; Ida Elise Langleite; Ragna-Johanne Bakksjø; Lutz Andreas Eichacker; Clemens Furnes
Journal:  FEBS Open Bio       Date:  2020-03-16       Impact factor: 2.693

8.  Cellular Factor XIII, a Transglutaminase in Human Corneal Keratocytes.

Authors:  Zsuzsanna Z Orosz; Helga Bárdos; Amir H Shemirani; Ildikó Beke Debreceni; Riitta Lassila; Antti S Riikonen; Johanna A Kremer Hovinga; Theo G Seiler; Hendrika A van Dorland; Verena Schroeder; Zoltán Boda; László Nemes; Beatrice Früh Eppstein; Bence Nagy; Andrea Facskó; János Kappelmayer; László Muszbek
Journal:  Int J Mol Sci       Date:  2019-11-27       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.